肝细胞癌的组织学亚型与基因突变及分子肿瘤分类相关
研究对343例手术切除的肝细胞癌样本进行病理复核、免疫组化、基因表达谱和测序,发现CTNNB1与TP53突变互斥并定义两个表型不同的主要组;WHO组织学亚型与分子特征密切相关,新命名的巨梁状-巨块型亚型与不良生存相关,并在TCGA数据中得到验证。
要点
- CTNNB1突变(40%)与TP53突变(21%)互斥,定义两个表型不同的肝细胞癌主要组。
- WHO组织学亚型与分子特征密切相关,硬化型与TSC1/TSC2突变相关。
- 新命名的巨梁状-巨块型亚型与不良生存、血管侵犯、TP53突变及FGF19扩增相关。
核心结论
- 肝细胞癌表型与基因突变及转录组分类紧密相关。
研究设计与样本
- 对343例手术切除的肝细胞癌样本进行病理复核、免疫组化、基因表达谱分析和测序。
主要发现
- CTNNB1突变占40%,TP53突变占21%,两者互斥并定义两个表型不同的主要组。
- CTNNB1突变肿瘤大(p=0.002)、高分化(p<0.001)、胆汁淤积(p<0.001),呈微梁状(p<0.001)和假腺管状(p<0.001)模式,无炎性浸润(p<0.001)。
- TP53突变肿瘤低分化(p<0.001),呈致密模式(p=0.02),多核(p=0.01)和多形性(p=0.02)细胞,频繁血管侵犯(p=0.02)。
- 硬化型亚型与TSC1/TSC2突变(p=0.005)、上皮-间质转化和祖细胞表达谱相关。
- 脂肪肝炎型亚型常见IL-6/JAK/STAT激活,无CTNNB1、TERT和TP53通路改变(p=0.01)。
关键数值与推荐
- 病理复核识别新亚型巨梁状-巨块型,与不良生存(p<0.001)、高血清甲胎蛋白水平(p=0.02)、血管侵犯(p<0.001)、TP53突变(p<0.001)和FGF19扩增(p=0.02)相关,并在TCGA数据中得到验证。
- 肝细胞癌病理特征与转录组分类整合显示表型不同的肿瘤亚类与G1-G6亚组密切相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Our increasing understanding of hepatocellular carcinoma (HCC) biology holds promise for personalized care, however its translation into clinical practice requires a precise knowledge of its relationship to tumour phenotype. METHODS: We aimed at investigating molecular-phenotypic correlations in a large series of HCC. To this purpose, 343 surgically resected HCC samples were investigated by pathological review, immunohistochemistry, gene expression profiling and sequencing. RESULTS: CTNNB1 (40%) and TP53 (21%) mutations were mutually exclusive and defined two major groups of HCC characterized by distinct phenotypes. CTNNB1 mutated tumours were large (p=0.002), well-differentiated (p<0.001), cholestatic (p<0.001), with microtrabecular (p<0.001) and pseudoglandular (p<0.001) patterns and without inflammatory infiltrates (p<0.001). TP53 mutated tumours were poorly differentiated (p<0.001) with a compact pattern (p=0.02), multinucleated (p=0.01) and pleomorphic (p=0.02) cells and frequent vascular invasion (p=0.02). World Health Organization (WHO) classification of histological subtypes were also strongly related to molecular features. The scirrhous subtype was associated with TSC1/TSC2 mutations (p=0.005), epithelial-to-mesenchymal transition and a progenitor expression profile. The steatohepatitic subtype showed frequent IL-6/JAK/STAT activation without CTNNB1, TERT and TP53 pathway alterations (p=0.01). Pathological review identified a novel subtype, designated as "macrotrabecular-massive" associated with poor survival (p<0.001), high alpha-fetoprotein serum level (p=0.02), vascular invasion (p<0.001), TP53 mutations (p<0.001) and FGF19 amplifications (p=0.02), features also validated in The Cancer Genome Atlas (TCGA) data. Finally, integration of HCC pathological characteristics with its transcriptomic classification showed phenotypically distinct tumour subclasses closely related to G1-G6 subgroups. CONCLUSION: HCC phenotypes are tightly associated with gene mutations and transcriptomic classification. These findings may help in translating our knowledge of HCC biology into clinical practice. Lay summary: HCC is a very heterogenous tumour, both at the pathological and molecular levels. We show here that HCC phenotype is tightly associated to its molecular alterations and underlying oncogenic pathways.
引用
- Calderaro J, Couchy G, Imbeaud S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol. 2017. PMID: 28532995. doi:10.1016/j.jhep.2017.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。